WO2010071358A2 - Method of preparing ezetimibe and intermediates used therein - Google Patents
Method of preparing ezetimibe and intermediates used therein Download PDFInfo
- Publication number
- WO2010071358A2 WO2010071358A2 PCT/KR2009/007535 KR2009007535W WO2010071358A2 WO 2010071358 A2 WO2010071358 A2 WO 2010071358A2 KR 2009007535 W KR2009007535 W KR 2009007535W WO 2010071358 A2 WO2010071358 A2 WO 2010071358A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- compound
- molar equivalents
- equivalents based
- mixture
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 38
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 title claims abstract description 28
- 229960000815 ezetimibe Drugs 0.000 title claims abstract description 27
- 239000000543 intermediate Substances 0.000 title abstract description 13
- 150000001875 compounds Chemical class 0.000 claims description 94
- 238000006243 chemical reaction Methods 0.000 claims description 28
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 20
- -1 borane compound Chemical class 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 17
- 239000003054 catalyst Substances 0.000 claims description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 238000005859 coupling reaction Methods 0.000 claims description 9
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 239000002841 Lewis acid Substances 0.000 claims description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- 229910000085 borane Inorganic materials 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 150000002466 imines Chemical class 0.000 claims description 6
- 150000007517 lewis acids Chemical class 0.000 claims description 6
- BDOLXPFAFMNDOK-UHFFFAOYSA-N oxazaborolidine Chemical compound B1CCON1 BDOLXPFAFMNDOK-UHFFFAOYSA-N 0.000 claims description 6
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 claims description 6
- UORVGPXVDQYIDP-UHFFFAOYSA-N trihydridoboron Substances B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 claims description 6
- LEIMLDGFXIOXMT-UHFFFAOYSA-N trimethylsilyl cyanide Chemical compound C[Si](C)(C)C#N LEIMLDGFXIOXMT-UHFFFAOYSA-N 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- VMKAFJQFKBASMU-QGZVFWFLSA-N (r)-2-methyl-cbs-oxazaborolidine Chemical compound C([C@@H]12)CCN1B(C)OC2(C=1C=CC=CC=1)C1=CC=CC=C1 VMKAFJQFKBASMU-QGZVFWFLSA-N 0.000 claims description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 claims description 4
- NHGXDBSUJJNIRV-UHFFFAOYSA-M tetrabutylammonium chloride Chemical compound [Cl-].CCCC[N+](CCCC)(CCCC)CCCC NHGXDBSUJJNIRV-UHFFFAOYSA-M 0.000 claims description 4
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 3
- 229910052744 lithium Inorganic materials 0.000 claims description 3
- 238000007363 ring formation reaction Methods 0.000 claims description 3
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 claims description 3
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- 150000001408 amides Chemical class 0.000 claims description 2
- OVVMHZRGSHTZDB-UHFFFAOYSA-N dibutylboron Chemical compound CCCC[B]CCCC OVVMHZRGSHTZDB-UHFFFAOYSA-N 0.000 claims description 2
- LZWQNOHZMQIFBX-UHFFFAOYSA-N lithium;2-methylpropan-2-olate Chemical compound [Li+].CC(C)(C)[O-] LZWQNOHZMQIFBX-UHFFFAOYSA-N 0.000 claims description 2
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 claims description 2
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 claims description 2
- 238000005984 hydrogenation reaction Methods 0.000 abstract description 4
- 238000002425 crystallisation Methods 0.000 abstract description 3
- 230000008025 crystallization Effects 0.000 abstract description 3
- 206010003210 Arteriosclerosis Diseases 0.000 abstract description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract description 2
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 53
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
- 239000007787 solid Substances 0.000 description 20
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- 239000002904 solvent Substances 0.000 description 15
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- 239000012044 organic layer Substances 0.000 description 14
- 239000011541 reaction mixture Substances 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 11
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 10
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 238000005160 1H NMR spectroscopy Methods 0.000 description 6
- 238000001556 precipitation Methods 0.000 description 6
- 238000006722 reduction reaction Methods 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 0 **(*)(CO)COC(CCCC1(c(cc2)ccc2F)OCC(*)(*)*CO1)=O Chemical compound **(*)(CO)COC(CCCC1(c(cc2)ccc2F)OCC(*)(*)*CO1)=O 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- QDMNNMIOWVJVLY-MRVPVSSYSA-N (4s)-4-phenyl-1,3-oxazolidin-2-one Chemical compound C1OC(=O)N[C@H]1C1=CC=CC=C1 QDMNNMIOWVJVLY-MRVPVSSYSA-N 0.000 description 2
- VNNJGDYPPLXJFF-UHFFFAOYSA-N 4-[(4-fluorophenyl)iminomethyl]phenol Chemical compound C1=CC(O)=CC=C1C=NC1=CC=C(F)C=C1 VNNJGDYPPLXJFF-UHFFFAOYSA-N 0.000 description 2
- RGHHSNMVTDWUBI-UHFFFAOYSA-N 4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1 RGHHSNMVTDWUBI-UHFFFAOYSA-N 0.000 description 2
- ZBQROUOOMAMCQW-UHFFFAOYSA-N 5-(4-fluorophenyl)-5-oxopentanoic acid Chemical compound OC(=O)CCCC(=O)C1=CC=C(F)C=C1 ZBQROUOOMAMCQW-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- KRZCOLNOCZKSDF-UHFFFAOYSA-N 4-fluoroaniline Chemical compound NC1=CC=C(F)C=C1 KRZCOLNOCZKSDF-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- JRLPEMVDPFPYPJ-UHFFFAOYSA-N CCc1ccc(C)cc1 Chemical compound CCc1ccc(C)cc1 JRLPEMVDPFPYPJ-UHFFFAOYSA-N 0.000 description 1
- SROIXYVDELULJN-UHFFFAOYSA-N Cc(cc1)ccc1C(NC1C=CC(F)=CC1)=C Chemical compound Cc(cc1)ccc1C(NC1C=CC(F)=CC1)=C SROIXYVDELULJN-UHFFFAOYSA-N 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- RYIVGSLCRJFFMU-UODIDJSMSA-N [4-[(2s,3r)-1-(4-fluorophenyl)-3-[(3s)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl]phenyl] 2,2-dimethylpropanoate Chemical compound C1=CC(OC(=O)C(C)(C)C)=CC=C1[C@H]1N(C=2C=CC(F)=CC=2)C(=O)[C@@H]1CC[C@H](O)C1=CC=C(F)C=C1 RYIVGSLCRJFFMU-UODIDJSMSA-N 0.000 description 1
- VAGGHQTWQWUYDO-UHFFFAOYSA-N [4-[(4-fluorophenyl)iminomethyl]phenyl] 2,2-dimethylpropanoate Chemical compound C1=CC(OC(=O)C(C)(C)C)=CC=C1C=NC1=CC=C(F)C=C1 VAGGHQTWQWUYDO-UHFFFAOYSA-N 0.000 description 1
- XNPXYWHATQBVDV-UHFFFAOYSA-N [4-[5-cyano-1-(4-fluoroanilino)-5-(4-fluorophenyl)-2-(2-oxo-4-phenyl-1,3-oxazolidine-3-carbonyl)-5-trimethylsilyloxypentyl]phenyl] 2,2-dimethylpropanoate Chemical compound C1=CC(OC(=O)C(C)(C)C)=CC=C1C(C(CCC(O[Si](C)(C)C)(C#N)C=1C=CC(F)=CC=1)C(=O)N1C(OCC1C=1C=CC=CC=1)=O)NC1=CC=C(F)C=C1 XNPXYWHATQBVDV-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- MNFORVFSTILPAW-UHFFFAOYSA-N azetidin-2-one Chemical class O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 description 1
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- ZDQWVKDDJDIVAL-UHFFFAOYSA-N catecholborane Chemical compound C1=CC=C2O[B]OC2=C1 ZDQWVKDDJDIVAL-UHFFFAOYSA-N 0.000 description 1
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001906 cholesterol absorption Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229960002163 hydrogen peroxide Drugs 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229910001623 magnesium bromide Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000003863 metallic catalyst Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- SIOVKLKJSOKLIF-HJWRWDBZSA-N trimethylsilyl (1z)-n-trimethylsilylethanimidate Chemical compound C[Si](C)(C)OC(/C)=N\[Si](C)(C)C SIOVKLKJSOKLIF-HJWRWDBZSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
Definitions
- the present invention relates to an improved method for preparing ezetimibe and novel intermediates used therein.
- Ezetimibe the azetidinone derivative of formula 1 , has been used as a drug for preventing and treating arteriosclerosis, which is effective in decreasing cholesterol absorption in the intestine as well as in inhibiting cholesterol synthesis together with statins in the liver:
- Me is methyl
- Ph is phenyl
- Bn is Benzyl
- Bn is Benzyl
- WO 2007072088 and WO 2007120824 disclose a method for preparing ezetimibe comprising the step of introducing a ketal protecting group to the ketone of formula K, as shown in Reaction Scheme 3.
- this method has the problems that the removal of the protecting group does not precede easily and an expensive metallic catalyst is required for conducting an asymmetric reduction of the compound of formula Q to obtain the compound of formula R.
- X and Y are each independently hydrogen or optionally substituted alkyl, n is O to 3, Ph is phenyl, and Prot is a hydroxyl protecting group.
- U.S. Pat. No. 6,207,822 discloses a method for preparing ezetimibe comprising the steps of subjecting: the compound of formula U to an asymmetric reduction reaction in the presence of (R)-methyl CBS oxazaborolidine to prepare the compound of formula V; the compound of formula V and imine to hydroxyl-protecting with TMS-Cl simultaneously, then to convert into the compound of formula W through Mannich coupling reaction, and the compound of formula W to react with tetrabutylammonium fluoride/N,O-bis(trimethylsilyl)acetamide to prepare the beta-lactam compound of formula X, as shown in Reaction Scheme 4.
- this method suffers from the problem that 10 to 20 % of the compound of formula W in the above Mannich coupling reaction step is converted back to the compound of formula V due to the presence of an acid used therein for quenching the reaction.
- a method for preparing ezetimibe of formula 1 comprising: subjecting the compound of formula 2 to a coupling reaction with the imine of formula 6 in the presence of a Lewis acid and a base to prepare the compound of formula 3 ; conducting a cyclization reaction of the compound of formula 3 in the presence of a base to prepare the compound of formula 4; carrying out asymmetric reduction of the compound of formula 4 in the presence of a borane compound and a chiral catalyst to prepare the compound of formula 5; and removing the hydroxyl protecting group of the compound of formula 5 in the presence of a base,
- Ph is phenyl
- TMS is trimethylsilyl
- Piv is trimethylacetyl.
- the preparation method according to the present invention is characterized in that the compound of formula 3 prepared by coupling the compound of formula 2 with the compound of formula 6 is cyclized to obtain the compound of formula 4 and the compound of formula 5 prepared by asymmetric reduction of the compound of formula 4 is used as an intermediate for preparing ezetimibe of formula 1 , and further in that the compound of formula 2 is prepared by a reaction of the compound of formula 7 with cyanotrimethylsilane in the presence of a halogen catalyst.
- the ezetimibe of formula 1 according to the present invention can be prepared from the compound of formula 8 by the method illustrated in Reaction Scheme 5, but not limited thereto: Reaction Scheme 5
- the ketone compound of formula 7 which is used as an intermediate in the present invention is prepared by conducting a coupling reaction of the carboxylic acid of formula 8 with the chiral auxiliary of formula 9.
- the chiral auxiliary of formula 9 is used in an amount ranging from 0.9 to 1.1 molar equivalents based on the carboxylic acid of formula 8.
- the coupling reaction is carried out in a solvent containing N,N'-dicyclohexylcarboimide and 4-dimethylaminopyridine.
- N,N'-dicyclohexylcarboimide is used in an amount ranging from 0.8 to 1.1 molar equivalents based on the carboxylic acid of formula 8
- 4-dimethylaminopyridine is used in an amount ranging from 0.05 to 0.5 molar equivalents, preferably 0.1 molar equivalents, based on the carboxylic acid of formula 8.
- the solvent include, but are not limited to, dichloromethane, chloroform, and a mixture thereof.
- the ketal compound of formula 2 a novel intermediate for preparing ezetimibe, is prepared by treating the ketone compound of formula 7 with cyanotrimethylsilane in the presence of a halogen catalyst.
- the amount of cyanotrimethylsilane used is in the range of 1 to 3 molar equivalents, preferably
- halogen catalyst examples include bromine, iodine, etc, preferably iodine.
- the halogen catalyst is used in an amount ranging from 0.01 to 0.1 molar equivalents based on the ketone compound of formula 7.
- reaction is carried out at a temperature of -10 to 25 ° C .
- solvent used in this step examples include, but are not limited to, dichloromethane, chloroform, toluene, tetrahydrofuran, N,N-dimethylformamide, dimethylsulfoxide, and a mixture thereof.
- the compound of formula 3 is prepared by conducting a coupling reaction of the ketal compound of formula 2 obtained in step ii with the imine compound of formula 6 having the protected hydroxyl group in the presence of a Lewis acid and a base.
- the amount of the compound of formula 6 used in this step is in the range of 1 to 3 molar equivalents, preferably 1.2 molar equivalents, based on the ketal compound of formula 2.
- Examples of the Lewis acid include, but are not limited to, titanium tetrachloride, dibutylboron triplate, and a mixture thereof, and the amount of the Lewis acid used in this step is in the range of 1 to 3 molar equivalents, preferably 1 to 1.5 molar equivalents, based on the ketal compound of formula 2.
- Examples of the base include, but are not limited to, amine having C 1-6 alkyl such as triethylamine, diisopropylethylamine, and tributylamine, and the amount of the base used in this step is in the range of 1 to 3 molar equivalents, preferably 1.3 to 1.7 molar equivalents, based on the ketal compound of formula 2.
- the reaction is carried out at a temperature of -75 °C to 25 ° C , preferably -45 ° C to -30 "C .
- the solvent used in this step include, but are not limited to, dichloromethane, chloroform, toluene, tetrahydrofuran, ethyl acetate, and a mixture thereof.
- Step iv the beta-lactam cyclic compound of formula 4 is prepared by the cyclization of the compound of formula 3 obtained in step iii in the presence of a base.
- Examples of the base include, but are not limited to, n-butyl lithium, lithium t-butoxide, lithium hexamethyldisilyl amide, and a mixture thereof, and the amount of the base used in this step is in the range of 1 to 3 molar equivalents based on the compound of formula 3.
- reaction is carried out at a temperature of -20 " C to 25 °C , preferably -5 ° C to 5 ° C .
- Examples of the solvent used in this step include, but are not limited to, dichloromethane, chloroform, tetrahydrofuran, and a mixture thereof.
- the compound of formula 5 is prepared by carrying out asymmetric reduction of the beta-lactam cyclic compound of formula 4 obtained in step iv in the presence of a borane compound and a chiral catalyst.
- the term "chiral catalyst” which is also called an asymmetric catalysis, refers to a material which allows a non-chiral compound to convert into a chiral compound having an optical activity by asymmetric reduction of the carbonyl group of the non-chiral compound.
- the chiral catalyst as used herein include, but are not limited to (R)-methyl-CBS oxazaborolidine, (R)-propyl-CBS oxazaborolidine, (R)-butyl-CBS oxazaborolidine, (R)-o-tollyl-CBS oxazaborolidine, and a mixture thereof.
- the amount of the chiral catalyst used in this step is in the range of 0.05 to 0.3 molar equivalents, preferably 0.09 to 0.11 molar equivalents, based on the compound of formula 4.
- the borane compound include, but are not limited to, borane-dimethylsulfide, borane-tetrahydrofuran, catecholborane and a mixture thereof.
- the amount of the borane compound used in this step is in the range of 1 to 3 molar equivalents, preferably 1.3 to 1.7 molar equivalents, based on the compound of formula 4. It is preferable that the reaction is carried out at a temperature of -30 °C to
- solvent used in this step examples include, but are not limited to, dichloromethane, chloroform, tetrahydrofuran, diethyl ether, toluene, and a mixture thereof, preferably tetrahydrofuran.
- the compound of formula 1 is prepared by removing the hydroxyl protecting group of the compound of formula 5 obtained in step v in the presence of a base.
- a base include, but are not limited to, lithium hydroxide, sodium hydroxide, potassium hydroxide, tetrabutylammonium fluoride, tetrabutylammonium chloride, tetrabutylammonium bromide, and a mixture thereof.
- the amount of the base used in this step is in the range of 1 to 4 molar equivalents, preferably 1.5 to 2 molar equivalents, based on the compound of formula 5.
- reaction is carried out at a temperature of -20 ° C to 0 0 C .
- solvent used in this step examples include, but are not limited to, methanol, ethanol, propanol, isopropanol, butanol, acetonitril, 1,4-dioxane, acetone, tetrahydrofuran, dichloromethane, chloroform, and a mixture thereof.
- the hydroxyl-protected imine compound of formula 6 obtained in step iii is prepared by the method illustrated in Reaction Scheme 6, but not limited thereto: Reaction Scheme 6
- TEA is triethylamine
- the novel compound of formula 6 is prepared by allowing 4-[(4-fluorophenylimino)-methyl]phenol (Imine-A) to react with trimethylacetylchloride in the presence of triethylamine.
- Imine-A is prepared by the method disclosed in U.S. Pat. No. 6,207,822.
- the reaction is carried out in a solvent at a temperature of 0 ° C to 25 ° C .
- the solvent include, but are not limited to, dichloromethane, chloroform, tetrahydrofuran, and a mixture thereof.
- Example 1 Preparation of ezetimibe (1-1) Preparation of 3-[5-(fluorophenyl)-l,5-dioxapentyl]-4(S)- phenyl-2-oxazolidinone (Formula 7)
- the reaction mixture was washed successively with 640 mi of water at 0 ° C and 640 mi of saturated sodium chloride, and the organic layer was isolated.
- the organic layer was dried over anhydrous magnesium sulfate and distilled under a reduced pressure to remove the solvent.
- the residue thus obtained was dissolved in 256 mi of ethyl acetate with heating, and then cooled to room temperature to induce the precipitation of a solid. 768 mi of n-hexane was added to the solid and stirred for 1 hour to obtain 123 g of the title compound as a white solid (yield: 58%).
- the organic layer was washed with 100 mi of saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and distilled under a reduced pressure to remove the solvent. 50 mi of dichloromethane and 0.92 mi of triethylamine were added to the residue thus obtained. 0.82 mi of trimethylacetyl chloride was added thereto and stirred. The reaction mixture thus obtained was extracted with 50 mi of water and 10 M of 3N hydrochloric acid, and the organic layer was isolated. The organic layer was washed successively with 50 mi of sodium bicarbonate and 50 mi of saturated sodium chloride, dried over anhydrous magnesium sulfate, and distilled under a reduced pressure. The residue thus obtained was dissolved in 60 mi of methanol. 20 mi of water was added thereto and stirred for 1 hour to induce the precipitation of a solid. The solid was isolated by filtering to obtain 5.2 g of the title compound as a pale yellow solid (yield: 80 %).
- the reaction mixture thus obtained was extracted with 30 ml of ethyl acetate and 30 ml of water, and the organic layer was isolated.
- the organic layer was washed successively with 20 ml of 2 N sulfuric acid and 20 ml of saturated sodium chloride, dried over anhydrous magnesium sulfate, and distilled under a reduced pressure to remove the solvent.
- the residue thus obtained was dissolved in 50 ml of methanol, and 20 ml of water was added thereto and stirred for 1 hour to induce the precipitation of a solid.
- the solid was isolated by filtering to obtain 8.82 g of the title compound as a pale yellow solid (yield: 88%).
Abstract
Disclosed is a method for preparing ezetimibe which is effective for preventing or treating arteriosclerosis, and novel intermediates used therein. In accordance with the method which does not use expensive reagents, unwanted diastereoisomers can be easily removed by a step-by-step crystallization procedure, and the ezetimibe of formula 1 can be prepared in a high yield without the use of a hydrogenation procedure under a high pressure.
Description
METHOD OF PREPARING EZETIMIBE AND INTERMEDIATES USED
THEREIN
FIELD OF THE INVENTION
The present invention relates to an improved method for preparing ezetimibe and novel intermediates used therein.
BACKGROUND OF THE INVENTION
Ezetimibe, the azetidinone derivative of formula 1 , has been used as a drug for preventing and treating arteriosclerosis, which is effective in decreasing cholesterol absorption in the intestine as well as in inhibiting cholesterol synthesis together with statins in the liver:
Various methods for preparing ezetimibe have been disclosed, e.g., in reissued U.S. Pat. No. 37721, U.S. Pat. No. 5,856,473, U.S. Pat. No. 6,207,822, WO 2007072088, and WO 2007120824. The reissued U.S. Pat. No. 37721 discloses a method for preparing ezetimibe using the procedure shown in Reaction Scheme 1. However, this method have disadvantages in that the synthesis of the compound of formula F through the reaction of the carbonyl chloride of formula E with fluorophenyl magnesium bromide gives an unsatisfactorily low yield, a purification process using column chromatography is required for obtaining the compound of formula F, and a hydrogenation reaction under a high pressure is required to eliminate the benzyl protecting group of the compound of formula G.
Reaction Scheme 1
wherein Me is methyl, Ph is phenyl, and Bn is Benzyl.
U.S. Pat. No. 5,856,473 discloses a method for preparing ezetimibe which involves the steps shown in Reaction Scheme 2. This method, however, has the disadvantages that the reaction to prepare the compound of formula I must be conducted at -78 °C , a high-pressure hydrogenation reaction is required to eliminate the benzyl protecting group of the compound of formula J, and a purification process using column chromatography is required for obtaining the non-crystalline compound of formula J.
Reaction Scheme 2
wherein Bn is Benzyl.
WO 2007072088 and WO 2007120824 disclose a method for preparing ezetimibe comprising the step of introducing a ketal protecting group to the ketone of formula K, as shown in Reaction Scheme 3. However, this method has the problems that the removal of the protecting group does not precede easily and an expensive metallic catalyst is required for conducting an asymmetric reduction of the compound of formula Q to obtain the compound of formula R.
Reaction Scheme 3
O
wherein X and Y are each independently hydrogen or optionally substituted alkyl, n is O to 3, Ph is phenyl, and Prot is a hydroxyl protecting group.
U.S. Pat. No. 6,207,822 discloses a method for preparing ezetimibe
comprising the steps of subjecting: the compound of formula U to an asymmetric reduction reaction in the presence of (R)-methyl CBS oxazaborolidine to prepare the compound of formula V; the compound of formula V and imine to hydroxyl-protecting with TMS-Cl simultaneously, then to convert into the compound of formula W through Mannich coupling reaction, and the compound of formula W to react with tetrabutylammonium fluoride/N,O-bis(trimethylsilyl)acetamide to prepare the beta-lactam compound of formula X, as shown in Reaction Scheme 4. However, this method suffers from the problem that 10 to 20 % of the compound of formula W in the above Mannich coupling reaction step is converted back to the compound of formula V due to the presence of an acid used therein for quenching the reaction.
Reaction Scheme 4
wherein t-Bu is tert-butyl, Ph is phenyl, and TMS is trimethylsilyl.
The present inventors have therefore endeavored to develop a novel method for preparing ezetimibe which is free from the above-mentioned problems associated with the conventional methods.
SUMMARY OF THE INVENTION
Accordingly, it is a primary object of the present invention to provide an improved method for preparing ezetimibe and intermediates used therein.
In accordance with one aspect of the present invention, there is provided a method for preparing ezetimibe of formula 1 comprising: subjecting the compound of formula 2 to a coupling reaction with the imine of formula 6 in the presence of a Lewis acid and a base to prepare the compound of formula 3 ; conducting a cyclization reaction of the compound of formula 3 in the presence of a base to prepare the compound of formula 4; carrying out asymmetric reduction of the compound of formula 4 in the presence of a borane compound and a chiral catalyst to prepare the compound of formula 5; and removing the hydroxyl protecting group of the compound of formula 5 in the presence of a base,
Ph is phenyl,
TMS is trimethylsilyl, and
Piv is trimethylacetyl.
In accordance with another aspect of the present invention, there is provided the compound of formula 2 as an intermediate which is useful for preparing ezetimibe of formula 1 :
wherein Ph and TMS have the same meanings as indicated above.
In accordance with a further aspect of the present invention, there is provided the compound of formula 3 as an intermediate which is useful for preparing ezetimibe of formula 1 :
In accordance with a further aspect of the present invention, there is provided the compound of formula 4 as an intermediate which is useful for preparing ezetimibe of formula 1 :
In accordance with a still further aspect of the present invention, there is provided the compound of formula 5 as an intermediate which is useful for preparing ezetimibe of formula 1 :
wherein Piv has the same meaning as indicated above.
In accordance with a still yet further aspect of the present invention, there is provided the compound of formula 6 as an intermediate which is useful for preparing ezetimibe of formula 1 :
DETAILED DESCRIPTION OF THE INVENTION
The preparation method according to the present invention is characterized in that the compound of formula 3 prepared by coupling the compound of formula 2 with the compound of formula 6 is cyclized to obtain the compound of formula 4 and the compound of formula 5 prepared by asymmetric reduction of the compound of formula 4 is used as an intermediate for preparing ezetimibe of formula 1 , and further in that the compound of formula 2 is prepared by a reaction of the compound of formula 7 with cyanotrimethylsilane in the presence of a halogen catalyst.
In an embodiment, the ezetimibe of formula 1 according to the present invention can be prepared from the compound of formula 8 by the method illustrated in Reaction Scheme 5, but not limited thereto:
Reaction Scheme 5
Step i
In this step, the ketone compound of formula 7 which is used as an intermediate in the present invention is prepared by conducting a coupling reaction of the carboxylic acid of formula 8 with the chiral auxiliary of formula 9. The chiral auxiliary of formula 9 is used in an amount ranging from 0.9 to 1.1 molar equivalents based on the carboxylic acid of formula 8.
It is preferable that the coupling reaction is carried out in a solvent containing N,N'-dicyclohexylcarboimide and 4-dimethylaminopyridine. In this case, N,N'-dicyclohexylcarboimide is used in an amount ranging from 0.8 to 1.1 molar equivalents based on the carboxylic acid of formula 8, and 4-dimethylaminopyridine is used in an amount ranging from 0.05 to 0.5 molar equivalents, preferably 0.1 molar equivalents, based on the carboxylic acid of formula 8. Examples of the solvent include, but are not limited to,
dichloromethane, chloroform, and a mixture thereof.
Step ii
The ketal compound of formula 2, a novel intermediate for preparing ezetimibe, is prepared by treating the ketone compound of formula 7 with cyanotrimethylsilane in the presence of a halogen catalyst. The amount of cyanotrimethylsilane used is in the range of 1 to 3 molar equivalents, preferably
1.3 to 1.7 molar equivalents, based on the ketone compound of formula 7.
Examples of the halogen catalyst include bromine, iodine, etc, preferably iodine. The halogen catalyst is used in an amount ranging from 0.01 to 0.1 molar equivalents based on the ketone compound of formula 7.
It is preferable that the reaction is carried out at a temperature of -10 to 25 °C .
Examples of the solvent used in this step include, but are not limited to, dichloromethane, chloroform, toluene, tetrahydrofuran, N,N-dimethylformamide, dimethylsulfoxide, and a mixture thereof.
Step iii
In this step, the compound of formula 3 is prepared by conducting a coupling reaction of the ketal compound of formula 2 obtained in step ii with the imine compound of formula 6 having the protected hydroxyl group in the presence of a Lewis acid and a base.
The amount of the compound of formula 6 used in this step is in the range of 1 to 3 molar equivalents, preferably 1.2 molar equivalents, based on the ketal compound of formula 2.
Examples of the Lewis acid include, but are not limited to, titanium tetrachloride, dibutylboron triplate, and a mixture thereof, and the amount of the Lewis acid used in this step is in the range of 1 to 3 molar equivalents, preferably 1 to 1.5 molar equivalents, based on the ketal compound of formula 2. Examples of the base include, but are not limited to, amine having C1-6 alkyl such as triethylamine, diisopropylethylamine, and tributylamine, and the
amount of the base used in this step is in the range of 1 to 3 molar equivalents, preferably 1.3 to 1.7 molar equivalents, based on the ketal compound of formula 2.
It is preferable that the reaction is carried out at a temperature of -75 °C to 25 °C , preferably -45 °C to -30 "C . Examples of the solvent used in this step include, but are not limited to, dichloromethane, chloroform, toluene, tetrahydrofuran, ethyl acetate, and a mixture thereof.
Step iv In this step, the beta-lactam cyclic compound of formula 4 is prepared by the cyclization of the compound of formula 3 obtained in step iii in the presence of a base.
Examples of the base include, but are not limited to, n-butyl lithium, lithium t-butoxide, lithium hexamethyldisilyl amide, and a mixture thereof, and the amount of the base used in this step is in the range of 1 to 3 molar equivalents based on the compound of formula 3.
It is preferable that the reaction is carried out at a temperature of -20 "C to 25 °C , preferably -5 °C to 5 °C .
Examples of the solvent used in this step include, but are not limited to, dichloromethane, chloroform, tetrahydrofuran, and a mixture thereof.
Step v
In this step, the compound of formula 5 is prepared by carrying out asymmetric reduction of the beta-lactam cyclic compound of formula 4 obtained in step iv in the presence of a borane compound and a chiral catalyst.
As used herein, the term "chiral catalyst" which is also called an asymmetric catalysis, refers to a material which allows a non-chiral compound to convert into a chiral compound having an optical activity by asymmetric reduction of the carbonyl group of the non-chiral compound. Examples of the chiral catalyst as used herein include, but are not limited to (R)-methyl-CBS oxazaborolidine, (R)-propyl-CBS oxazaborolidine, (R)-butyl-CBS
oxazaborolidine, (R)-o-tollyl-CBS oxazaborolidine, and a mixture thereof. The amount of the chiral catalyst used in this step is in the range of 0.05 to 0.3 molar equivalents, preferably 0.09 to 0.11 molar equivalents, based on the compound of formula 4. Examples of the borane compound include, but are not limited to, borane-dimethylsulfide, borane-tetrahydrofuran, catecholborane and a mixture thereof. The amount of the borane compound used in this step is in the range of 1 to 3 molar equivalents, preferably 1.3 to 1.7 molar equivalents, based on the compound of formula 4. It is preferable that the reaction is carried out at a temperature of -30 °C to
0 °C .
Examples of the solvent used in this step include, but are not limited to, dichloromethane, chloroform, tetrahydrofuran, diethyl ether, toluene, and a mixture thereof, preferably tetrahydrofuran.
Step vi
In this step, the compound of formula 1 is prepared by removing the hydroxyl protecting group of the compound of formula 5 obtained in step v in the presence of a base. Examples of the base include, but are not limited to, lithium hydroxide, sodium hydroxide, potassium hydroxide, tetrabutylammonium fluoride, tetrabutylammonium chloride, tetrabutylammonium bromide, and a mixture thereof. The amount of the base used in this step is in the range of 1 to 4 molar equivalents, preferably 1.5 to 2 molar equivalents, based on the compound of formula 5.
It is preferable that the reaction is carried out at a temperature of -20 °C to 0 0C .
Examples of the solvent used in this step include, but are not limited to, methanol, ethanol, propanol, isopropanol, butanol, acetonitril, 1,4-dioxane, acetone, tetrahydrofuran, dichloromethane, chloroform, and a mixture thereof.
Further, the hydroxyl-protected imine compound of formula 6 obtained in step iii is prepared by the method illustrated in Reaction Scheme 6, but not limited thereto: Reaction Scheme 6
wherein Piv is trimethylacetyl radical, TEA is triethylamine.
The novel compound of formula 6 is prepared by allowing 4-[(4-fluorophenylimino)-methyl]phenol (Imine-A) to react with trimethylacetylchloride in the presence of triethylamine.
Imine-A is prepared by the method disclosed in U.S. Pat. No. 6,207,822.
It is preferable that the reaction is carried out in a solvent at a temperature of 0 °C to 25 °C . Examples of the solvent include, but are not limited to, dichloromethane, chloroform, tetrahydrofuran, and a mixture thereof.
In accordance with the inventive preparation method which does not use expensive reagents, unwanted diastereoisomers can be easily removed by a step-by-step crystallization procedure, and the ezetimibe of formula 1 can be prepared in a high yield without the use of a hydrogenation procedure under a high pressure.
The following Preparation Examples and Examples are intended to further illustrate the present invention without limiting its scope.
Example 1: Preparation of ezetimibe
(1-1) Preparation of 3-[5-(fluorophenyl)-l,5-dioxapentyl]-4(S)- phenyl-2-oxazolidinone (Formula 7)
200 g of 5-(4-fluorophenyl)-5-oxopentanoic acid of formula 8, 16O g of (S)-4-phenyloxazolidine-2-one of formula 9, and 11.6 g of 4-dimethylaminopyridine were dissolved in 600 m£ of dichloromethane to prepare a reaction mixture. A solution which was prepared by dissolving 157 g of N,N'-dicyclohexylcarboimide in 200 ml of dichloromethane was added to the reaction mixture and stirred for 2 hours. After completion of the reaction, the resulting reaction mixture was filtered to remove by-products. The filtrate thus obtained was washed successively with 1 I of 6N HCl, 1 € of water, and 1 € of saturated sodium chloride, dried over anhydrous magnesium sulfate, filtered, and distilled under a reduced pressure to remove the solvent. The residue thus obtained was dissolved in 2 I of methanol by heating and cooled to induce crystallization. 2 £ of water was added thereto and stirred for 30 min. The solid thus obtained was isolated by filtering to obtain 289 g of the title compound as a white solid (yield: 86%).
1H NMR(300MHz, CDCl3) : δ 7.92 (2H, M), 7.35-7.13 (5H, m), 7.04 (2H, m), 5.43 (IH, q), 4.75(1H, t), 4.22 (IH, q), 3.05-2.93 (4H, m), 2.03 (2H, m)
(1-2) Preparation of 2-(4-fluorophenyl)-6-oxo-6-(2-oxo-4-phenyl oxazoIidine-3-yl)-2-trimethylsilyloxy hexane nitrile (Formula 2)
100 g of
3-[5-(fiuorophenyl)- 1 ,5-dioxapentyl]-4(S)-phenyl-2-oxazolidinone obtained in (1-1) was dissolved in 1 £ of dichloromethane and cooled to 0 °C . 3.55 g of iodine was added thereto, followed by adding thereto 53 ml of cyanotrimethylsilane over 20 min. After 2 hrs, the reaction mixture was washed twice with 500 ml of aqueous Na2S2O3 and the organic layer was isolated. The organic layer was dried over anhydrous magnesium sulfate and distilled under a reduced pressure to obtain 127.9 g of the title compound (yield: 100 %). 1H NMR (300MHz, CDCl3) : δ 7.35-7.14 (7H, m), 6.94 (2H, t), 5.26 (2H, dd), 4.56 (IH, t), 4.15 (2H, dd), 2.83 (2H, t), 1.90-1.48 (4H, m), 0.02 (9H, s)
(1-3) Preparation of 2,2-dimethyl-propionic acid 4-[(4-fluorophenyl imino)-methyl] -phenyl ester (Formula 6)
180 g of 4- [(4-fluorophenylimino)-methyl] -phenol, which had been prepared by the reaction of 4-hydroxybenzaldehyde with 4-fluoroaniline according to the method described in U.S. Pat. No. 6,207,822, was dissolved in
1.26 € of dichloromethane and stirred to obtain a slurry. 354 mi of triethylamine and 113 mi of trimethylacetyl chloride were added to the slurry and stirred for 30 min. The reaction mixture thus obtained was combined with 630 mi of water to obtain an separated organic layer, which was further washed with 1 € of water. The washed organic layer was dried over anhydrous magnesium sulfate and distilled under a reduced pressure to remove the solvent.
The residue thus obtained was dissolved in 540 mi of n-hexane and stirred at
0 °C for 1 hour to induce the precipitation of a solid. The solid was filtered to obtain 233 g of the title compound as a white solid (yield: 93 %).
1H NMR (300MHz, CDCl3) : δ 8.42 (IH, s), 7.91(2H, d), 7.22-67.16 (4H, m), 7.07 (2H, t), 1.38 (9H, s)
(1-4) Preparation of 2,2-dimethylpropionic acid 4-[5-cyano -5-(4-fluorophenyl)-l-(4-fluorophenylamino)-2-(2-oxo-4-phenyl-oxazolidine-3 -carbonyl) -5-trimethylsilyloxypentyl] -phenyl ester (Formula 3)
127.9 g of the compound of formula 2 obtained in (1-2) and 101.08 g of the imine compound of formula 6 obtained in (1-3) were dissolved in 1.02 I of dichloromethane and cooled at -40 °C . 73.69 mi of diisopropylethylamine was added thereto and maintained for 10 min. 0.31 I of titanium tetrachloride (IM solution in CH2Cl2) was added thereto over 30 min and stirred for 30 min. After completion of the reaction, isopropyl alcohol/dichloromethane (256 m£/128 mi) were added to the reaction mixture thus obtained while maintaining at the temperature of -25 °C or less, and then heated to 0 °C . The reaction mixture was washed successively with 640 mi of water at 0 °C and 640 mi of saturated sodium chloride, and the organic layer was isolated. The organic layer was dried
over anhydrous magnesium sulfate and distilled under a reduced pressure to remove the solvent. The residue thus obtained was dissolved in 256 mi of ethyl acetate with heating, and then cooled to room temperature to induce the precipitation of a solid. 768 mi of n-hexane was added to the solid and stirred for 1 hour to obtain 123 g of the title compound as a white solid (yield: 58%).
1H NMR (300MHz, CDCl3) : δ 7.25-6.84 (13H, m), 6.66-6.62 (2H, m), 6.27-6.25 (2H, m), 5.31 (IH, m), 4.84 (IH, d), 4.58 (IH, m), 4.39 (IH, m), 4.27 (IH, m), 4.10 (2H, dd), 1.97-1.43 (4H, m), 1.28 (9H, m) 0.02 (9H, s)
(1-5) Preparation of 2,2-dimethyl-propionic acid 4-{l-(4-fluorophenyl)
-3-[3-(4-fluorophenyl)-3-oxopropyl]-4-oxoazetidine-2-yI}-phenyl ester
(Formula 4)
15.9 mi of lithium hexamethyldisilylamide (IM solution in Toluene) was added to a solution which was prepared by dissolving 10 g of the compound of formula 3 obtained in (1-4) in 50 mi of dichloromethane and cooling at 0 °C , and stirred for 30 min. 20 mi of methanol was added thereto and further stirred for 15 min to obtain a reaction mixture. 50 il of dichloromethane, 50 mi of water, and 50 ml of 3N hydrochloric acid were added successively to the reaction mixture and stirred to isolate an aqueous layer. The aqueous layer was extracted with 50 mi dichloromethane and the organic layer was isolated. The organic layer was washed with 100 mi of saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and distilled under a reduced pressure to remove the solvent. 50 mi of dichloromethane and 0.92 mi of triethylamine were added to the residue thus obtained. 0.82 mi of trimethylacetyl chloride was added thereto and stirred. The reaction mixture thus obtained was extracted with 50 mi of water and 10 M of 3N hydrochloric acid, and the organic layer was isolated. The organic layer was washed successively with 50 mi of sodium bicarbonate and 50 mi of saturated sodium chloride, dried over anhydrous magnesium sulfate, and distilled under a reduced pressure. The residue thus obtained was dissolved in 60 mi of methanol. 20 mi of water was added thereto and stirred for 1 hour to induce the precipitation of a solid. The solid
was isolated by filtering to obtain 5.2 g of the title compound as a pale yellow solid (yield: 80 %).
1H NMR (300MHz, CDCl3) : δ 8.01-7.96 (2H, m), 7.35-6.90 (1OH, m), 4.75 (IH, s), 3.29-3.11 (3H, m), 2.42-2.27 (2H, m), 1.34 (9H, s)
(1-6) Preparation of 4-((2S,3R)-l-(4-fluorophenyl)-3-((S)-3-(4-fluoro phenyl)-3-hydroxypropyl)-4-oxoazetidine-2-yl)-phenyl pivalate (Formula 5)
30 ml of tetrahydrofuran was placed in a reactor and cooled to -25 "C . 2.89 ml of BMS (Borane-dimethylsulfide complex) and 2 ml of (R)-(+)-2-methyl-CBS-oxazaborolidine(lM solution in Toluene) were added thereto and stirred for 15 min. The reaction mixture thus obtained was added to a solution which was prepared by dissolving 1O g of the compound of formula 4 obtained in (1-5) in 30 ml of tetrahydrofuran over 30 min, and stirred for 1.5 hour. After completion of the reaction, 30 ml of 10% hydrogen-peroxide was added thereto and stirred for 10 min to quench. The reaction mixture thus obtained was extracted with 30 ml of ethyl acetate and 30 ml of water, and the organic layer was isolated. The organic layer was washed successively with 20 ml of 2 N sulfuric acid and 20 ml of saturated sodium chloride, dried over anhydrous magnesium sulfate, and distilled under a reduced pressure to remove the solvent. The residue thus obtained was dissolved in 50 ml of methanol, and 20 ml of water was added thereto and stirred for 1 hour to induce the precipitation of a solid. The solid was isolated by filtering to obtain 8.82 g of the title compound as a pale yellow solid (yield: 88%).
1R NMR (300MHz, CDCl3) : δ 7.33-6.82(12H, m), 4.70 (IH, t), 4.61 (IH, d), 3.08 (IH, q), 2.19(1H, s), 2.07-1.84 (4H, m), 1.30 (9H, m)
(1-7) Preparation of l-(4-fluorophenyI)-3-[3-(4-fluorophenyl)- 3-hydroxypropyl] -4-(4-hydroxyphenyl)-azetidine-2-one (Formula 1)
1O g of the compound of formula 5 obtained in (1-6) was dissolved in 70 ml of tetrahydrofuran and cooled to - 15 °C . The reaction solution thus obtained was added to a solution which was prepared by dissolving 1.6 g of sodium
hydroxide in 30 ml of methanol, and stirred for 30 min. The reaction mixture thus obtained was extracted with 100 ml of IN hydrochloric acid and 50 ml of ethyl acetate, and the aqueous layer was isolated. The aqueous layer was extracted with 30 mi of ethyl acetate and the organic layer was isolated. The organic layer was washed three times with 50 ml of water, dried over anhydrous magnesium sulfate, and distilled under a reduced pressure to remove the solvent. The residue thus obtained was dissolved in 50 ml of methanol. 37.5 ml of water was added thereto and stirred for 1 hour to induce the precipitation of a solid. The solid was isolated by filtering to obtain 7.63 g of the title compound as a white solid (yield: 92%).
1H NMR (300MHz, DMSO-d6) : 69.53 (IH, s), 7.46-7.09 (1OH, m), 6.78 (2H, d), 5.29 (IH, d), 4.89 (IH, s), 4.51 (IH, d), 3.09 (IH, m), 1.88-1.73 (4H, m)
(1-8) Purification of ezetimibe 10 g of ezetimibe obtained in (1-7) was dissolved in 60 ml of acetonitrile at 40 °C and cooled to room temperature. 60 ml of water was added thereto and stirred for 1 hour to induce the precipitation of a solid. The solid was isolated by filtering to obtain 9.0 g of the title compound as a white solid (yield: 90 %).
While the invention has been described with respect to the above specific embodiments, it should be recognized that various modifications and changes may be made to the invention by those skilled in the art which also fall within the scope of the invention as defined by the appended claims.
Claims
1. A method for preparing ezetimibe of formula 1 , comprising:
(i) subjecting the compound of formula 2 to a coupling reaction with the imine of formula 6 in the presence of a Lewis acid and a base to prepare the compound of formula 3;
(ii) conducting a cyclization reaction of the compound of formula 3 in the presence of a base to prepare the compound of formula 4;
(iii) carrying out asymmetric reduction of the compound of formula 4 in the presence of a borane compound and a chiral catalyst to prepare the compound of formula 5; and
(iv) removing the hydroxyl protecting group of the compound of formula 5 in the presence of a base:
Ph is phenyl,
TMS is trimethylsilyl, and
Piv is trimethylacetyl.
2. The method of claim 1, wherein the amount of the compound of formula 6 used in step i is in the range of 1 to 3 molar equivalents based on the compound of formula 2.
3. The method of claim 1, wherein the Lewis acid used in step i is selected from the group consisting of titanium tetrachloride, dibutylboron triplate, and a mixture thereof, and used in an amount ranging from 1 to 3 molar equivalents based on the compound of formula 2.
4. The method of claim 1, wherein the base used in step i is selected from the group consisting of triethylamine, diisopropylethylamine, tributylamine, and a mixture thereof, and used in an amount ranging from 1 to 3 molar equivalents
based on the compound of formula 2.
5. The method of claim 1, wherein the base used in step ii is selected from the group consisting of lithium hexamethyldisilyl amide, n-butyl lithium, lithium t-butoxide, and a mixture thereof, and used in an amount ranging from 1 to 3 molar equivalents based on the compound of formula 3.
6. The method of claim 1, wherein the chiral catalyst used in step iii is selected from the group consisting of (R)-methyl-CBS oxazaborolidine, (R)-propyl-CBS oxazaborolidine, (R)-butyl-CBS oxazaborolidine, (R)-o-tollyl-CBS oxazaborolidine, and a mixture thereof, and used in an amount ranging from 0.05 to 0.3 molar equivalents based on the compound of formula 4.
7. The method of claim 1, wherein the amount of the borane compound used in step iii is in the range of 1 to 3 molar equivalents based on the compound of formula 4.
8. The method of claim 1, wherein the base used in step iv is selected from the group consisting of lithium hydroxide, sodium hydroxide, potassium hydroxide, tetrabutylammonium fluoride, tetrabutylammonium chloride, tetrabutylammonium bromide, and a mixture thereof, and used in an amount ranging from 1 to 4 molar equivalents based on the compound of formula 7.
9. The method of claim 1, wherein the compound of formula 2 is prepared by subjecting the compound of the formula 7 to a reaction with cyanotrimethylsilane in the presence of a halogen catalyst:
10. The method of claim 9, wherein the cyanotrimethylsilane is used in an amount ranging from 1 to 3 molar equivalents based on the compound of formula
7.
11. The method of claim 9, wherein the halogen catalyst is used in an amount ranging from 0.01 to 0.1 molar equivalents based on the compound of formula 7.
12. The method of claim 9, wherein the compound of formula 7 is prepared by conducting a coupling reaction of the compound of formula 8 with the compound of formula 9 in the presence of N,N'-dicyclohexylcarboimide and 4-dimethy laminopyridine :
13. The compound of formula 2 :
14. The compound of formula 3 :
16. The compound of formula 5:
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2008-0128457 | 2008-12-17 | ||
KR20080128457 | 2008-12-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010071358A2 true WO2010071358A2 (en) | 2010-06-24 |
WO2010071358A3 WO2010071358A3 (en) | 2010-09-10 |
Family
ID=42269242
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2009/007535 WO2010071358A2 (en) | 2008-12-17 | 2009-12-16 | Method of preparing ezetimibe and intermediates used therein |
Country Status (4)
Country | Link |
---|---|
KR (1) | KR101156588B1 (en) |
AR (1) | AR074752A1 (en) |
TW (1) | TW201028374A (en) |
WO (1) | WO2010071358A2 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012076030A1 (en) | 2010-12-10 | 2012-06-14 | Pharmathen S.A. | Process for the preparation of intermediate compounds useful in the preparation of ezetimibe |
CN103086938A (en) * | 2011-10-28 | 2013-05-08 | 沈阳药科大学 | Ezetimibe synthesis method |
CN103204795A (en) * | 2012-01-11 | 2013-07-17 | 重庆华邦胜凯制药有限公司 | Chiral azetidinone compound preparation method |
CN103373970A (en) * | 2012-04-16 | 2013-10-30 | 重庆圣华曦药业股份有限公司 | Synthetic method for Ezetimibe intermediate |
US9388440B2 (en) | 2009-04-01 | 2016-07-12 | Mylan Laboratories Limited | Enzymatic process for the preparation of (S)-5-(4-fluoro-phenyl)-5-hydroxy-1morpholin-4-yl-pentan-1-one, an intermediate of Ezetimibe and further conversion to Ezetimibe |
CN106831522A (en) * | 2015-12-03 | 2017-06-13 | 中国科学院上海有机化学研究所 | Lactam analog compound and preparation method thereof |
CN106967106A (en) * | 2017-04-24 | 2017-07-21 | 上海华源医药科技发展有限公司 | A kind of production method of Ezetimibe intermediate |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102078158B1 (en) | 2018-02-21 | 2020-02-17 | 강원대학교산학협력단 | Process for preparing Ezetimibe and intermediate thereof |
US11110444B2 (en) | 2019-12-30 | 2021-09-07 | Industrial Technology Research Institute | Chiral catalyst and heterogeneous chiral catalyst comprising the same |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5886171A (en) * | 1996-05-31 | 1999-03-23 | Schering Corporation | 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones |
US6207822B1 (en) * | 1998-12-07 | 2001-03-27 | Schering Corporation | Process for the synthesis of azetidinones |
WO2007072088A1 (en) * | 2005-12-20 | 2007-06-28 | Richter Gedeon Nyrt. | Process for the production of ezetimibe and intermediates used in this proces |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1137634B1 (en) * | 1998-12-07 | 2005-06-15 | Schering Corporation | Process for the synthesis of azetidinones |
US20070259845A1 (en) * | 2005-09-08 | 2007-11-08 | Kansal Vinod K | Processes for the preparation of (3R,4S)-4-((4-benzyloxy)phenyl)-1-(4-fluorophenyl)-3-((S)-3-(4-fluorophenyl)-3-hydroxypropyl)-2-azetidinone, an intermediate for the synthesis of ezetimibe |
-
2009
- 2009-12-15 AR ARP090104870A patent/AR074752A1/en not_active Application Discontinuation
- 2009-12-16 KR KR1020090125646A patent/KR101156588B1/en active IP Right Grant
- 2009-12-16 WO PCT/KR2009/007535 patent/WO2010071358A2/en active Application Filing
- 2009-12-16 TW TW098143111A patent/TW201028374A/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5886171A (en) * | 1996-05-31 | 1999-03-23 | Schering Corporation | 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones |
US6207822B1 (en) * | 1998-12-07 | 2001-03-27 | Schering Corporation | Process for the synthesis of azetidinones |
WO2007072088A1 (en) * | 2005-12-20 | 2007-06-28 | Richter Gedeon Nyrt. | Process for the production of ezetimibe and intermediates used in this proces |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9388440B2 (en) | 2009-04-01 | 2016-07-12 | Mylan Laboratories Limited | Enzymatic process for the preparation of (S)-5-(4-fluoro-phenyl)-5-hydroxy-1morpholin-4-yl-pentan-1-one, an intermediate of Ezetimibe and further conversion to Ezetimibe |
WO2012076030A1 (en) | 2010-12-10 | 2012-06-14 | Pharmathen S.A. | Process for the preparation of intermediate compounds useful in the preparation of ezetimibe |
CN103086938A (en) * | 2011-10-28 | 2013-05-08 | 沈阳药科大学 | Ezetimibe synthesis method |
CN103204795A (en) * | 2012-01-11 | 2013-07-17 | 重庆华邦胜凯制药有限公司 | Chiral azetidinone compound preparation method |
CN103204795B (en) * | 2012-01-11 | 2016-12-14 | 重庆华邦胜凯制药有限公司 | A kind of preparation method of chirality azetidinones |
CN103373970A (en) * | 2012-04-16 | 2013-10-30 | 重庆圣华曦药业股份有限公司 | Synthetic method for Ezetimibe intermediate |
CN106831522A (en) * | 2015-12-03 | 2017-06-13 | 中国科学院上海有机化学研究所 | Lactam analog compound and preparation method thereof |
CN106831522B (en) * | 2015-12-03 | 2021-06-08 | 中国科学院上海有机化学研究所 | Lactam compound and preparation method thereof |
CN106967106A (en) * | 2017-04-24 | 2017-07-21 | 上海华源医药科技发展有限公司 | A kind of production method of Ezetimibe intermediate |
Also Published As
Publication number | Publication date |
---|---|
KR101156588B1 (en) | 2012-06-20 |
AR074752A1 (en) | 2011-02-09 |
KR20100070305A (en) | 2010-06-25 |
WO2010071358A3 (en) | 2010-09-10 |
TW201028374A (en) | 2010-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010071358A2 (en) | Method of preparing ezetimibe and intermediates used therein | |
CA1310323C (en) | Process and preparing cis-1-carba(1-dethia)cephalosporins and intermediates therefor | |
CA2438961C (en) | Beta-lactam compounds, manufacturing methods of the compounds and serum hypocholesterolemic agents containing the compounds | |
JP2008540557A (en) | Process for producing phenol-type 4-biphenylylazetidin-2-one | |
US7067675B2 (en) | Process for ezetimibe intermediate | |
RU2650687C1 (en) | Method for obtaining azetidinone compounds and derivatives of azetidinone compounds | |
US7812179B2 (en) | Process for the preparation of atorvastatin and intermediates | |
WO2009067960A2 (en) | A method of manufacturing (3r,4s)-l-(4-fluorophenyl)-3-[(3s)-3-(4-fluorophenyl)-3- hydroxypropyl)]-4-(4-hydroxyphenyl)-2-azetidinone and its intermediates | |
WO2008106900A1 (en) | Method of manufacturing (3r, 4s) -1- (4-fluorophenyl) -3- [ (3s) -3- (4 -fluorophenyl) -3-hydroxypropyl) ] -4- (4-hyd roxyphenyl) -2-azetidinone | |
JP5095945B2 (en) | Process for producing 4-trifluoromethylnicotinic acid or a salt thereof | |
EP2414326B1 (en) | Intermediates in the preparation of 1,4-diphenyl azetidinone | |
KR20080011687A (en) | Process for production of 4-biphenylylazetidin-2-ones | |
WO2005066120A2 (en) | Process for asymmetric synthesis of hydroxy-alkyl substituted azetidinone derivatives | |
KR20090105309A (en) | Process for the preparation of optically active 5-hydroxy-3-oxoheptanoate derivatives | |
JP2005047803A (en) | Method for producing (3r,5s)-7-substituted-3,5-dihydroxyhept-6-enoic acid | |
WO2016115962A1 (en) | Preparation method for nebivolol intermediate and preparation method for nebivolol | |
JPS6328423B2 (en) | ||
JP2001131148A (en) | Method for depositing diastereomer crystal | |
JP5059355B2 (en) | Method for producing oxazolidine derivative | |
JP2005145833A (en) | Method for producing syn-1,3-diol compound | |
JPH03115260A (en) | Improved method for synthesis of beta-lactam using metal compound | |
JP5236627B2 (en) | Process for producing asymmetric tetra-substituted quinolone carboxylic acid and its intermediate | |
CA1332059C (en) | Process for preparing cis-1-carba(1-dethia)cephalosporins and intermediates therefor | |
JP2004002206A (en) | Method for producing optically active thiazolidinone derivative | |
WO2009104557A1 (en) | Process for production of n-(3-pyrrolidinyl)glycine derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09833636 Country of ref document: EP Kind code of ref document: A2 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09833636 Country of ref document: EP Kind code of ref document: A2 |